Core Viewpoint - Haofan Bio announced a revenue of 270 million yuan for the first half of 2025, representing a year-on-year growth of 20.10% [1] - The net profit attributable to shareholders of the listed company was 75.8848 million yuan, showing a year-on-year increase of 15.31% [1] - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves [1] Financial Performance - Revenue for the first half of 2025 reached 270 million yuan, up 20.10% compared to the previous year [1] - Net profit attributable to shareholders was 75.8848 million yuan, reflecting a growth of 15.31% year-on-year [1] Dividend Policy - The company has decided not to distribute cash dividends [1] - There will be no issuance of bonus shares [1] - No capital increase from reserves is planned [1]
昊帆生物：2025年上半年净利润同比增长15.31%